5 years of historical data (2021–2025) · Healthcare · Medical - Care Facilities
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Solventum Corporation trades at 8.4x earnings, 49% below its 5-year average of 16.4x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 23.7x, the stock trades at a discount of 65%.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Market Cap | $12.9B | $13.9B | $11.5B | — | — | — |
| Enterprise Value | $17.0B | $18.0B | $18.7B | — | — | — |
| P/E Ratio → | 8.36 | 8.92 | 23.93 | — | — | — |
| P/S Ratio | 1.55 | 1.67 | 1.39 | — | — | — |
| P/B Ratio | 2.58 | 2.75 | 3.88 | — | — | — |
| P/FCF | — | — | 14.25 | — | — | — |
| P/OCF | 34.88 | 37.64 | 9.68 | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
Solventum Corporation's enterprise value stands at 7.8x EBITDA, 22% below its 5-year average of 10.0x. The Healthcare sector median is 13.8x, placing the stock at a 44% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| EV / Revenue | — | 2.17 | 2.27 | — | — | — |
| EV / EBITDA | 7.81 | 8.27 | 11.77 | — | — | — |
| EV / EBIT | 7.81 | — | 19.26 | — | — | — |
| EV / FCF | — | — | 23.26 | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Solventum Corporation earns an operating margin of 26.2%. Operating margins have expanded from 20.6% to 26.2% over the past 3 years, signaling improving operational efficiency. Return on equity of 38.9% is exceptionally high. ROIC of 16.9% represents solid returns on invested capital.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Gross Margin | 53.5% | 53.5% | 55.6% | 57.3% | 57.7% | 60.2% |
| Operating Margin | 26.2% | 26.2% | 12.6% | 20.6% | 20.8% | 23.0% |
| Net Profit Margin | 18.7% | 18.7% | 5.8% | 16.4% | 16.5% | 17.9% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| ROE | 38.9% | 38.9% | 6.6% | 11.5% | 11.3% | 12.1% |
| ROA | 10.8% | 10.8% | 3.4% | 9.8% | 9.7% | 10.4% |
| ROIC | 16.9% | 16.9% | 5.2% | 8.1% | 10.7% | 11.8% |
| ROCE | 19.0% | 19.0% | 8.6% | 13.8% | 13.6% | 14.8% |
Solvency and debt-coverage ratios — lower is generally safer
Solventum Corporation carries a Debt/EBITDA ratio of 2.3x, which is manageable (26% below the sector average of 3.1x). Net debt stands at $4.2B ($5.0B total debt minus $878M cash). Interest coverage of 6.3x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Debt / Equity | 1.00 | 1.00 | 2.71 | 0.71 | — | — |
| Debt / EBITDA | 2.31 | 2.31 | 5.03 | 3.69 | — | — |
| Net Debt / Equity | — | 0.82 | 2.45 | 0.70 | -0.01 | -0.01 |
| Net Debt / EBITDA | 1.91 | 1.91 | 4.56 | 3.60 | -0.03 | -0.04 |
| Debt / FCF | — | — | 9.00 | 4.99 | -0.04 | -0.05 |
| Interest Coverage | 6.29 | 6.29 | 2.82 | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.23x means Solventum Corporation can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.89x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 1.46x to 1.23x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Current Ratio | 1.23 | 1.23 | 1.20 | 1.46 | 1.70 | 1.56 |
| Quick Ratio | 0.89 | 0.89 | 0.84 | 0.96 | 1.04 | 0.98 |
| Cash Ratio | 0.28 | 0.28 | 0.28 | 0.11 | 0.05 | 0.06 |
| Asset Turnover | — | 0.58 | 0.57 | 0.59 | 0.60 | 0.58 |
| Inventory Turnover | 3.63 | 3.63 | 3.79 | 4.09 | 3.93 | 4.00 |
| Days Sales Outstanding | — | 45.33 | 54.35 | 58.47 | 52.57 | 52.58 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Solventum Corporation does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business. The earnings yield of 12.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Earnings Yield | 12.0% | 11.2% | 4.2% | — | — | — |
| FCF Yield | — | — | 7.0% | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | — | — | — |
| Shares Outstanding | — | $175M | $174M | $173M | $172M | $172M |
Compare SOLV with 6 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| SOLVYou | $13B | 8.4 | 7.8 | — | 53.5% | 26.2% | 38.9% | 16.9% | 2.3 |
| HCSG | $2B | 26.9 | 24.0 | 12.0 | 13.0% | 2.6% | 10.6% | 7.7% | 0.3 |
| AMN | $987M | -5.1 | 29.2 | 4.1 | 30.8% | -3.4% | -19.1% | -3.9% | 15.4 |
| CCRN | $281M | -19.8 | 319.8 | 2.5 | 20.4% | -1.3% | -3.3% | -3.2% | 6.1 |
| CCEL | $27M | 67.4 | 10.0 | 7.5 | 75.2% | 10.9% | — | — | 3.3 |
| AMS | $14M | 6.4 | 7.7 | — | 32.4% | -9.9% | 7.8% | -5.8% | 6.9 |
| SYRA | $60000 | -0.2 | — | — | 20.7% | -47.2% | -109.1% | -294.7% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 5 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how SOLV stacks up against sector leader Healthcare Services Group, Inc..
Start ComparisonSolventum Corporation's current P/E ratio is 8.4x. The historical average is 16.4x.
Solventum Corporation's current EV/EBITDA is 7.8x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 10.0x.
Solventum Corporation's return on equity (ROE) is 38.9%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 16.1%.
Based on historical data, Solventum Corporation is trading at a P/E of 8.4x. Compare with industry peers and growth rates for a complete picture.
Solventum Corporation has 53.5% gross margin and 26.2% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
Solventum Corporation's Debt/EBITDA ratio is 2.3x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.